Mind Medicine (MindMed) Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 56.8 million compared to USD 93.04 million a year ago. Basic loss per share from continuing operations was USD 1.84.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.135 USD | -3.15% | -5.84% | +122.54% |
13/05 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
08/05 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+122.54% | 60Cr | |
+64.72% | 6.26TCr | |
-1.45% | 4.12TCr | |
+44.76% | 4.03TCr | |
-8.93% | 2.79TCr | |
+13.33% | 2.62TCr | |
-21.80% | 1.91TCr | |
+4.96% | 1.31TCr | |
+25.47% | 1.23TCr | |
+28.61% | 1.21TCr |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022